USFDAMay 8, 2026, 05:21 PM
Argenx VYVGART FDA label expanded for all adult gMG serotypes
AI Summary
Argenx announced that the U.S. FDA approved a label expansion for VYVGART and VYVGART Hytrulo for the treatment of all serotypes of adult patients with generalized myasthenia gravis (gMG). This approval is based on data from the Phase 3 ADAPT SERON study, which showed rapid, significant, and sustained symptom improvements across anti-MuSK-Ab positive, anti-LRP4-Ab positive, and triple seronegative patients. The expanded indication simplifies treatment decisions for clinicians and addresses a significant unmet medical need for gMG patients without detectable AChR antibodies.
Key Highlights
- FDA approved label expansion for VYVGART and VYVGART Hytrulo for all adult gMG serotypes.
- Approval based on Phase 3 ADAPT SERON study data.
- Primary endpoint met (p=0.0068) with statistically significant improvement in MG-ADL score.
- Overall population showed a 3.35-point improvement in MG-ADL total score at week 4.
- Approximately 20% of gMG patients do not have detectable AChR antibodies.
- Anti-MuSK antibodies detected in 1-10% of gMG patients.
- Anti-LRP4 antibodies detected in 1-5% of gMG patients.
- Approximately 10% of patients are triple seronegative.